The telehealth firm has deployed its product for scheduled virtual visits across the Military Health System, “the most significant growth initiative in our company’s history,” said CFO and COO Mark Hirschhorn.
Amwell narrows losses in Q1 amid military contract rollout Read More »
Executives said Thursday that the company has already laid off employees to help mitigate the effects of the Trump administration’s tariff policies.
Cardinal Health cuts employees to offset up to $300M tariff charge Read More »
CEO Kevin Lobo said that without the tariffs, the company would have “raised our earnings without question.”
Stryker expects $200M tariff hit, lowers earnings forecast Read More »
Intuitive secured a single port robot clearance, Resmed bought sleep testing facility Virtuox, and Precision Neuroscience hired an executive to support its BCI commercialization plans.
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility Read More »
After multiple rounds of layoffs that cut Kronos down to just 10 people, the small molecule biotech has accepted a buyout offer from Kevin Tang’s Concentra Biosciences.
Kronos Accepts $35M Concentra Buyout as Walls Close In Read More »
No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative medicines by 90% and mislead U.S. policymakers into thinking Americans are overpaying.
Low-Price Drug Nations Catching ‘Free Ride’ on US Innovation, Report Says Read More »
Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, Pliant is paring back its workforce.
Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials Read More »
A new Trump administration report said teens struggling with gender dysphoria should undergo “exploratory” therapy and that conversion therapy was misunderstood.
Trump HHS tiptoes around endorsing conversion therapy for transgender minors Read More »
As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and facts, there may be a more sinister force at play: censorship.
Biomedical Innovation in Jeopardy as Kennedy Distorts, Denies Scientific Truths Read More »
Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy instead of tariffs to promote domestic pharma manufacturing.
